# Frederik Marmé

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/frederik-marme/

## Facts

| Field | Value |
| --- | --- |
| Citations | 22,845 |
| Field | Breast Cancer Treatment Studies |
| h-index | 69 |
| i10-index | 219 |
| Last Known Institution | Heidelberg University |
| OpenAlex ID | https://openalex.org/A5011232197 |
| ORCID iD | https://orcid.org/0000-0002-6591-3367 |
| Works | 776 |

## Researcher papers

- [Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer](https://scholariq.org/papers/olaparib-plus-bevacizumab-as-first-line-maintenance-in-ovarian-cancer/)
- [Large-scale genotyping identifies 41 new loci associated with breast cancer risk](https://scholariq.org/papers/large-scale-genotyping-identifies-41-new-loci-associated-with-breast-cancer-risk/)
- [Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay](https://scholariq.org/papers/identification-of-a-population-of-blood-circulating-tumor-cells-from-breast/)
- [Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials](https://scholariq.org/papers/clinical-and-molecular-characteristics-of-her2-low-positive-breast-cancer-pooled/)
- [Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants](https://scholariq.org/papers/prediction-of-breast-cancer-risk-based-on-profiling-with-common-genetic-variants/)
- [Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer](https://scholariq.org/papers/multiple-independent-variants-at-the-tert-locus-are-associated-with-telomere/)
- [A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)](https://scholariq.org/papers/a-randomized-phase-iii-trial-to-evaluate-rucaparib-monotherapy-as-maintenance/)
- [ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease](https://scholariq.org/papers/esgo-esmo-esp-consensus-conference-recommendations-on-ovarian-cancer-pathology/)
- [Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial](https://scholariq.org/papers/axillary-surgery-in-breast-cancer-primary-results-of-the-insema-trial/)
- [European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer](https://scholariq.org/papers/european-experts-consensus-brca-homologous-recombination-deficiency-testing-in/)
- [Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial](https://scholariq.org/papers/bevacizumab-and-platinum-based-combinations-for-recurrent-ovarian-cancer-a/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)

## Researcher university

- [Heidelberg University](https://scholariq.org/institutions/heidelberg-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.